Allergan Annual Report - Corporate Solutions

+WE ARE EXPANDING OUR WORLD.Allergan has established a leadership presence in morethan 100 countries around the world so that we can bringtreatment advances developed and established in the UnitedStates to new markets, improving patient care with newmeans. Our continued expansion outside of the United Statesincludes emerging markets with fast-growing economiessuch as China, Korea, Brazil, India, Russia, the Ukraine andother countries where populations are vast, the need issubstantial, and the desire for health and well-being —especially as populations age — is universal.In Korea, we pursued this goal in 2009 by moving froman all-distributor model to a direct sales and marketingpresence in these regions to be closer to our customersin both our core pharmaceuticals and medical aestheticssegments, establishing a joint venture in eye care with ourlong-term partner. In China, we also established our owndirect sales and marketing operation. In India, where weare the No. 1 eye care pharmaceutical company (1) as a resultof a successful joint venture established in 1994 , wealso expanded our scope by creating direct operations forneurosciences and facial aesthetics. As a result of our focuson emerging markets, Korea was the first country outsideof the United States to approve LATISSE ® . Also, in 2009,LUMIGAN ® 0.01% was approved in Brazil as the secondmarket in the world after Canada. BOTOX ® was approvedin China for the treatment of glabellar lines. In Russia andthe Ukraine, we have filed a complete portfolio of our mostup-to-date eye care products and expect approvals soon.But our global expansion has been driven by more thannew product approvals and the innovation behind them.Historically and around the world we’ve placed a premiumon engaging with our customers, patients and consumers innew ways. For our therapeutic businesses, we’ve placed evengreater emphasis on scientific exchange and communicatingimportant safety, efficacy and pharmacoeconomics data tophysicians, payors, and other key stakeholders. In medicalaesthetics, we’ve lived up to our role as industry leaders bybringing value-added training and business services in thesenewly established markets to our customers.By expanding our treatment portfolios and deepeningrelationships across national boundaries, health care systemsand cultures, we are creating new opportunities to pursuethe full potential of our innovation, while offering newoptions to millions more patients.(1) Allergan data on file.toGO“I want usWHERE we’reMore than 70 millionpeople worldwide sufferfrom glaucoma.**International Glaucoma Association. About Glaucoma. Available at:http:www.glaucoma-association.com. Accessed: February 22, 2010.needed,with the safest andmost efficacioustreatment options available. Innovationmeans little if people don’t haveaccess to it.”Tom KnoxVice President, ManagedMarkets and GovernmentAffairs/U.S.Married and father of three22 allergan annual report 2009 23